Correlation Between Karyopharm Therapeutics and Apellis Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Karyopharm Therapeutics and Apellis Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Karyopharm Therapeutics and Apellis Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Karyopharm Therapeutics and Apellis Pharmaceuticals, you can compare the effects of market volatilities on Karyopharm Therapeutics and Apellis Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Karyopharm Therapeutics with a short position of Apellis Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Karyopharm Therapeutics and Apellis Pharmaceuticals.

Diversification Opportunities for Karyopharm Therapeutics and Apellis Pharmaceuticals

-0.58

Correlation Coefficient

Karyopharm Therapeutics  Apellis Pharmaceuticals

Excellent diversification

The 3 months correlation between Karyopharm and Apellis is -0.58. Overlapping area represents the amount of risk that can be diversified away by holding Karyopharm Therapeutics and Apellis Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Apellis Pharmaceuticals and Karyopharm Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Karyopharm Therapeutics are associated (or correlated) with Apellis Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Apellis Pharmaceuticals has no effect on the direction of Karyopharm Therapeutics i.e., Karyopharm Therapeutics and Apellis Pharmaceuticals go up and down completely randomly.

Pair Corralation between Karyopharm Therapeutics and Apellis Pharmaceuticals

Given the investment horizon of 90 days Karyopharm Therapeutics is expected to under-perform the Apellis Pharmaceuticals. In addition to that, Karyopharm Therapeutics is 1.33 times more volatile than Apellis Pharmaceuticals. It trades about -0.04 of its total potential returns per unit of risk. Apellis Pharmaceuticals is currently generating about 0.0 per unit of volatility. If you would invest  3,629  in Apellis Pharmaceuticals on September 27, 2024 and sell it today you would lose (297.00) from holding Apellis Pharmaceuticals or give up 8.18% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Karyopharm Therapeutics  vs.  Apellis Pharmaceuticals

Karyopharm Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Karyopharm Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the recent confusion on Wall Street may also be a sign of long-lasting gains for the firm traders.

Apellis Pharmaceuticals

Risk-Adjusted Performance

6 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Apellis Pharmaceuticals are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak essential indicators, Apellis Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Karyopharm Therapeutics and Apellis Pharmaceuticals

The main advantage of trading using opposite Karyopharm Therapeutics and Apellis Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Karyopharm Therapeutics position performs unexpectedly, Apellis Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apellis Pharmaceuticals will offset losses from the drop in Apellis Pharmaceuticals' long position.

The idea behind Karyopharm Therapeutics and Apellis Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.